Search Results 1751-1760 of 19587 for Hemoglobin

  1. Continued type 2 diabetes mellitus remission independent of weight loss observed in patients after Roux-en-Y gastric bypass - Mayo Clinic

    Baseline insulin use, higher hemoglobin A1C levels and longer preoperative duration of T2DM were associated with T2DM recurrence, while weight recurrence was ...

  2. Neurology - Clinical trials - Mayo Clinic

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  3. Dasatinib And Quercetin With CAR T Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma - Mayo Clinic

    * Hemoglobin ≥ 8.0 g/dL (obtained ≤ 14 days prior to registration) * Absolute neutrophil count (ANC) ≥ 1,000/mm\^3 (obtained ≤ 14 days prior to ...

  4. Elotuzumab In Immunoglobulin G4-Related Disease (IgG4-RD) - Mayo Clinic

    Hemoglobin < 10 g/dL;; Platelet count < 75 x 10^9/L;; Estimated glomerular filtration rate (eGFR) ≤ 45 ml/minute/1.73m^2. The use of supplemental oxygen at ...

  5. Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis - Mayo Clinic

    Subjects with hemoglobin ≥ 10 g/dL. 9. Subjects with total bilirubin < 2× ULN. 10. Men and women of child-bearing potential (WOCBP) must agree to practice ...

  6. Testing the Addition of an Anti-cancer Drug, ASTX727, to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer - Mayo Clinic

    - Hemoglobin >= 9 g/dL or >= 5.6 mmol/L(within 14 days of registration) - Criteria must be met without packed red blood cell (pRBC) transfusion within the ...

  7. Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer - Mayo Clinic

    Hemoglobin ≥ 9 g/dL (uncorrected by RBC transfusion); Absolute neutrophil count (ANC) ≥ 1.5 × 109/L; Platelet count ≥ 100 × 109/L. Have adequate coagulation ...

  8. Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer - Mayo Clinic

    Hemoglobin >= 8 g/dL, within 2 weeks of randomization. Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (however, patients with known ...

  9. Dose-Escalation Study of cevostamab (BFCR4350A) in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) - Mayo Clinic

    Total hemoglobin ≥ 8 g/dL;; Patients who do not meet criteria for hematologic function because of MM-related cytopenias (e.g., due to extensive marrow ...

  10. A Study of Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That Is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery - Mayo Clinic

    Hemoglobin >= 9 g/dL, patients may receive transfusion to meet criterion (within 2 weeks of patient registration [for blood results] and 30 days of ...